Article and Video CATEGORIES

Cancer Journey

Search By

Vamsidhar Velcheti, MD, is a staff Physician of Medicine at the Cleveland Clinic Lerner College of Medicine and staff physician in the Department of Hematology and Oncology at Cleveland Clinic Taussig Cancer Institute. His specialty areas include lung cancer, mesothelioma, and thymic tumors and the use of novel immunotherapies for the treatment of lung cancer. Dr.

Lung Cancer Video Library - MET as a Target in Advanced NSCLC
Sat, 04/14/2018 - 14:59
Author
Vamsidhar Velcheti, MD, GRACE Faculty
MET as a Target in Advanced NSCLC Presented by Vamsidhar Velcheti, MD Hematology and Medical Oncology Cleveland Clinic Main Campus

Dr. Vamsidhar Velcheti, Thoracic Oncologist, Hematology and Medical Oncology, Cleveland Clinic, joined GRACE to discuss updates to our Lung Cancer Video Library. In this video, Dr. Velcheti discusses MET as a target in advanced non-small cell lung cancer.

 

TRANSCRIPT

So this is Vamsidhar Velcheti, I am a Thoracic Medical Oncologist at Cleveland Clinic and I am here to talk about MET in lung cancer. For the past couple of decades, we have investigated MET as a target for treatment in patients with lung cancer. MET is often upregulated or the protein expressional MET is increased in a lot of patients who have lung cancer. We have had multiple clinical trials and studies looking at various drugs that inhibit MET in lung cancer including Crizotinib. We know Crizotinib as an ALK inhibitor, but initially it was actually first developed as a MET inhibitor. There were other drugs including antibody-based treatments like MetMAb that targets MET. In those clinic trials, investigators have used protein expression or increased levels of the protein MET as a biomarker for response to these drugs. Unfortunately, all those trails were negative, and we did not see much benefit with using these drugs in patients who have increased protein expression of MET. However, some of those trails the challenge was to identify the right cutoffs of the protein expression and the biomarker related issues that actually lead to the failure of those trails. However, there are other mechanisms of upregulation of the MET pathway in lung cancer including MET amplifications and certain mutations in MET that activate the MET pathway like EXON 14 skipping mutations. When you have these genetic or genomic alterations in the RET gene, that activates the MET pathway. More recently we have seen some interesting data using Crizotinib which is a small molecule inhibitor of MET tyrosine kinase. Crizotinib has a very strong MET activity. Patients who have MET EXON 14 skipping mutations, Crizotinib appears to be a very actionable drug in those patients. However, we need more data in patients who have MET activating mutations and there are a lot of clinical trials which are currently ongoing including the NCI Match Trail that has an arm for patients who have a MET EXON 14 skipping mutation. So, I highly encourage patients who have a MET EXON 14 mutation to consider participating in some of these clinical trials to help our understanding of how those patients should be treated with targeted therapy targeting MET. There is a lot of promising new MET inhibitors in clinical development and hopefully we will see more positive news on that front.

 

 

 We would like to thank the following companies for their support of this program

 

                

 

 

                        

 

 
 

 

 


  

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Spanish Targeted Therapy Lung Cancer Patient Forum 2023
Video
2023 Terapias Dirigidas en el Foro de Pacientes con Cáncer de Pulmón El vídeo completo sin editar está disponible On Demand   View HERE  
Image
Spanish TTF 2023
Article
Únete a nosotros, sábado 12 de agosto a las 9:00 a.m.  En este foro anual de pacientes en vivo, los principales oncólogos torácicos de todo el mundo discuten temas relevantes para los objetivos del cáncer de pulmón, así como mutaciones raras.  
Image
Targeted Therapies in Lung Cancer Patient Forum 2023
Article
Thank you for joining us on Saturday for the 2023 Targeted Therapies in Lung Cancer Patient Forum! The full unedited versions of the 2023 Targeted Therapies in Lung Cancer Patient Forum presentations from the Mainstage and Second Stage, are now available OnDemand. These topics will be edited and offered as shorter videos in the coming weeks.  

Forum Discussions

Hi, I'm sorry you're having these issues.  The type of shoulder pain that feels like nerve pain is most likely nerve pain.  The type of tumor that causes similar shoulder pain...

Thank you so much for the response! I have seen a lot of your post on here and it's really awesome of you to take the time to reply to all...

ONKTALK is tomorrow. 

I hope to see you there.

The forum is now available on demand here.  Don't hesitate to ask questions as they come up. 

Take care,

Janine

Hi happybluesun,  Welcome to Grace.   I'm sorry your mom is going through this. 

 

Driver mutations are mutations that drive (or cause) the cancer.  Having more than one driver mutation is...

Hi Janine, thank you very much for your reply. As of June 2023, my mom has been prescribed Almonertibi Mesilate Tablet, a targeted therapy medicine made by the Chinese company Haosen...

Recent Comments

JOIN THE CONVERSATION
Thank you so much for the…
By Worried472 on Tue, 09/26/2023 - 12:44
Hi, I'm sorry you're having…
By JanineT GRACE … on Tue, 09/26/2023 - 11:24
The forum is now available…
By JanineT GRACE … on Mon, 09/25/2023 - 14:10
Reminder
By JanineT GRACE … on Fri, 09/22/2023 - 15:50